U.S. patent office rules in favour of Mylan
Natco Pharma said the U.S. Patent and Trademark Office (PTO) has ruled in the favour of its marketing partner Mylan with regard to patent claims pertaining to multiple sclerosis drug Copaxone. The pa
Natco Pharma said the U.S. Patent and Trademark Office (PTO) has ruled in the favour of its marketing partner Mylan with regard to patent claims pertaining to multiple sclerosis drug Copaxone. The pa
Leave a Reply
You must be logged in to post a comment.